FLT3 and acute myeloid leukemia: Based on the observation that AML LSC display aberrantly expressed cell surface target antigens and the encouraging preclinical data with CAR‐T cells recognizing CD123, CLL‐1, FLT3, and other surface molecules, there is hope that more specific and more effective CAR‐T cell based approaches will be developed for AML patients in the future.82, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117